119-HRES-1081 Journalist Public Summary

Headline Summary

A nonbinding House resolution to raise awareness of chordoma—a rare bone cancer—and to urge more funding and patient‑focused research efforts.

What It Does

H. Res. 1081 recognizes chordoma as a serious, hard‑to‑treat cancer of the skull and spine. It calls for increased support for early and accurate diagnosis, development of new treatments and diagnostics, fewer barriers between research and real‑world therapies, and more patient‑centric approaches to drug development.

By the Numbers

Who’s For It

• Sponsor: Rep. Johnson of Georgia, who introduced the measure on February 25, 2026.
• Patients and families facing chordoma, who stand to benefit from earlier diagnosis, more research options, and patient‑focused drug development (as emphasized in the resolution’s text).
• Lawmakers who support raising awareness of rare diseases and encouraging research without immediately changing spending or law.

Who’s Against It

• No organized opposition is noted in the text provided.
• Some lawmakers may be skeptical of nonbinding measures and prefer pursuing direct funding or statutory changes rather than statements of support.

What’s Next

• Status: Introduced on February 25, 2026 and referred to the House Committee on Energy and Commerce.
• Next steps: The committee may consider or discharge it; if brought to the floor and adopted, it would state the House’s position. As a simple House resolution, it does not go to the Senate or the President and does not become law.